Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 23:11:923.
doi: 10.3389/fphar.2020.00923. eCollection 2020.

Recent Developments in Pharmacological Effect, Mechanism and Application Prospect of Diazeniumdiolates

Bin Li  1 , Yue Ming  1 , Yao Liu  1 , Haiyan Xing  1 , Ruoqiu Fu  1 , Ziwei Li  1 , Rui Ni  1 , Li Li  1 , Dongyu Duan  1 , Jing Xu  1 , Chen Li  1 , Mingfeng Xiang  1 , Hongyu Song  1 , Jianhong Chen  1
Affiliations
Review

Recent Developments in Pharmacological Effect, Mechanism and Application Prospect of Diazeniumdiolates

Bin Li et al. Front Pharmacol. .

Abstract

Nitric oxide (NO) is a simple structured and unstable free radical molecule, which participates in the regulation of many pathophysiological processes. It functions both as a second messenger and as an endogenous neurotransmitter. Diazeniumdiolates (NONOates) are a series of compounds containing the functional parent nuclear structure of [N(O)NO]-, which are the most widely studied NO donors. NONOates are unstable and easy to release NO in physiological conditions. The biomedical applications and drug development of NO donor have attracted the scientists' attention in recent years. In this review, recent advances in NONOates research are highlighted in terms of chemical structures, molecular characteristics, pharmacological effects, and biomedical application prospects.

Keywords: application prospect; characteristics; diazeniumdiolates; pharmacological effect; structure.

PubMed Disclaimer

References

    1. Bahnson E. S., Vavra A. K., Flynn M. E., Vercammen J. M., Jiang Q., Schwartz A. R., et al. (2016). Long-term effect of PROLI/NO on cellular proliferation and phenotype after arterial injury. Free Radic. Biol. Med. 90, 272–286. 10.1016/j.freeradbiomed.2015.11.027 - DOI - PMC - PubMed
    1. Balez R., Ooi L. (2016). Getting to NO Alzheimer's Disease: Neuroprotection versus Neurotoxicity Mediated by Nitric Oxide. Oxid. Med. Cell. Longev. 2016, 3806157. 10.1155/2016/3806157 - DOI - PMC - PubMed
    1. Bobko A. A., Khramtsov V. V. (2014). Mechanistic studies of oxidative decomposition of Angeli's salt and PAPA NONOate. Nitric Oxide 40, 92–98. 10.1016/j.niox.2014.05.013 - DOI - PubMed
    1. Bullen M. L., Miller A. A., Dharmarajah J., Drummond G. R., Sobey C. G., Kemp-Harper B. K. (2011). Vasorelaxant and antiaggregatory actions of the nitroxyl donor isopropylamine NONOate are maintained in hypercholesterolemia. Am. J. Physiol. Heart Circ. Physiol. 301, 1405–1414. 10.1152/ajpheart.00489.2011 - DOI - PubMed
    1. Chen C., Shi Y., Li S., Qi Q., Gu L., Song J., et al. (2006. a). A glycosylated nitric oxide donor, beta-Gal-NONOate, and its site-specific antitumor activity. Arch. Pharm. (Weinheim) 339, 366–371. 10.1002/ardp.200500262 - DOI - PubMed

LinkOut - more resources